表紙:インターロイキン2受容体サブユニットα (TAC抗原/p55/CD25/IL2RA):パイプライン分析
市場調査レポート
商品コード
361640

インターロイキン2受容体サブユニットα (TAC抗原/p55/CD25/IL2RA):パイプライン分析

Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H2 2019

出版日: | 発行: Global Markets Direct | ページ情報: 英文 74 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.07円
インターロイキン2受容体サブユニットα (TAC抗原/p55/CD25/IL2RA):パイプライン分析
出版日: 2019年12月27日
発行: Global Markets Direct
ページ情報: 英文 74 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界各国でのインターロイキン2受容体サブユニットα (TAC抗原またはp55またはCD25またはIL2RA) のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

インターロイキン2受容体サブユニットα (TAC抗原/p55/CD25/IL2RA)の概要

治療薬の開発

  • インターロイキン2受容体サブユニットα (TAC抗原/p55/CD25/IL2RA)のパイプライン製品:概要

インターロイキン2受容体サブユニットα (TAC抗原/p55/CD25/IL2RA):各企業で開発中の治療薬

  • 治験の段階別
  • 治療領域別
  • 症状別

パイプライン製品の概略

  • 後期段階の製品
  • 初期段階の製品

各企業で開発中の治療薬

治療薬の評価

  • 単剤治療薬/併用治療薬の場合
  • 作用機序別
  • 投与方法別
  • 分子の種類別

治療薬の開発に従事している企業

  • AbbVie Inc.
  • Alkermes Plc
  • APT Therapeutics, Inc.
  • Mabtech Limited
  • Philogen S.p.A.

薬剤のプロファイル

  • APT-602
    • 製品概要
    • 作用機序
    • 研究開発 (R&D) の進展状況
  • バシリキシマブ
  • バシリキシマブのバイオベター
  • ダクリズマブ
  • Darleukin
  • RDB-1450

開発が休止状態の製品

注目すべき最新動向・プレスリリース (全15件)

付録

図表一覧

図表

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Alkermes Plc, H2 2019
  • Pipeline by Anaveon AG, H2 2019
  • Pipeline by APT Therapeutics Inc, H2 2019
  • Pipeline by Bristol-Myers Squibb Co, H2 2019
  • Pipeline by Courier Therapeutics Inc, H2 2019
  • Pipeline by Mabtech Ltd, H2 2019
  • Pipeline by Medicenna Therapeutics Corp, H2 2019
  • Pipeline by Nektar Therapeutics, H2 2019
  • Pipeline by Philogen SpA, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
目次
Product Code: GMDHC2076TDB

Summary

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Interleukin-2 receptor alpha is a protein that is encoded by the IL2RA gene. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of autoreactive T-cells.

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) pipeline Target constitutes close to 12 molecules. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 1, 3 and 5 respectively. Report covers products from therapy areas Immunology, Oncology, Cardiovascular, Dermatology and Metabolic Disorders which include indications Non-Small Cell Lung Cancer, Colorectal Cancer, Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Melanoma, Metastatic Melanoma, Plaque Psoriasis (Psoriasis Vulgaris), Renal Cell Carcinoma, Solid Tumor, Systemic Lupus Erythematosus, Atopic Dermatitis (Atopic Eczema), Autoimmune Disorders, Diabetic Nephropathy, Diffuse Large B-Cell Lymphoma, Gastric Cancer, Inflammation, Kidney Cancer (Renal Cell Cancer), Kidney Transplant Rejection, Lung Cancer, Ovarian Cancer, Pulmonary Arterial Hypertension, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Relapsed Acute Myeloid Leukemia, Skin Cancer, Soft Tissue Sarcoma, Stroke, Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Triple-Negative Breast Cancer (TNBC).

The latest report Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H2 2019, outlays comprehensive information on the Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA)
  • The report reviews Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Overview
  • Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Companies Involved in Therapeutics Development
  • Alkermes Plc
  • Anaveon AG
  • APT Therapeutics Inc
  • Bristol-Myers Squibb Co
  • Courier Therapeutics Inc
  • Mabtech Ltd
  • Medicenna Therapeutics Corp
  • Nektar Therapeutics
  • Philogen SpA
  • Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Drug Profiles
  • ALKS-4230 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • APT-602 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • basiliximab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • basiliximab biobetter - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CC-92252 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CT-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • daclizumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • darleukin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • daromun - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Fusion Protein to Antagonize IL2RB for Graft Versus Host Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MDNA-209 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NARA-1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NKTR-358 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • teleukin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Dormant Products
  • Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Product Development Milestones
  • Featured News & Press Releases
  • Nov 10, 2019: Nektar Therapeutics presents data from first-in-human phase 1a study on novel T regulatory cell stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology
  • Nov 08, 2019: Alkermes announces new data from ALKS 4230 clinical development program at Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
  • Nov 04, 2019: Alkermes to present data from ALKS 4230 clinical development program at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
  • Oct 21, 2019: Alkermes announces clinical collaboration with Fred Hutchinson Cancer Research Center for Novel Immuno-Oncology Drug Candidate ALKS 4230
  • Oct 07, 2019: Nektar Therapeutics announces initiation of two clinical studies of novel T regulatory cell stimulator NKTR-358 (LY3471851) in patients with psoriasis and atopic dermatitis
  • Jun 13, 2019: First-in-Human data presented from Phase 1a Study of NKTR-358, a novel t regulatory cell stimullator, at Annual European Congress of Rheumatology
  • Jun 12, 2019: Alkermes advances ALKS 4230 into monotherapy expansion Phase of ARTISTRY-1 in patients with renal cell carcinoma or melanoma
  • Jun 11, 2019: Nektar Therapeutics to host webcast conference call with immunology expert for analysts & investors during 2019 European Congress of Rheumatology (EULAR 2019)
  • Feb 26, 2019: Alkermes initiates clinical study of ALKS 4230 administered subcutaneously in patients with advanced solid tumors
  • Nov 06, 2018: Alkermes presents new data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting
  • Sep 11, 2018: Alkermes expands Phase l trial of ALKS 4230 for advanced solid tumours
  • Jul 18, 2018: Philogen receives orphan drug designation for the treatment of melanoma
  • May 18, 2018: EMA review of Zinbryta confirms medicine's risks outweigh its benefits
  • May 08, 2018: Nektar Therapeutics Announces Initiation of a Phase 1b Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, in Patients with Systemic Lupus Erythematosus
  • Mar 15, 2018: TGA: Zinbryta (daclizumab) Product withdrawn after overseas reports of inflammatory brain disorders
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer